Browse News
Filter News
Found 660,244 articles
-
Biopharma and life sciences companies from around the globe provide updates on their businesses and pipelines.
-
BioSpace recently spoke with Norman Sussman, chief medical officer at DURECT, a company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and lifesaving therapies based on its endogenous epigenetic regulator program.
-
Regardless of the field that you work in, incorporating leadership skills on your resume is a crucial step in making sure your application is noticed by employers.
-
NeuroPace, Inc. Announces Pricing of Initial Public Offering
4/22/2021
NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from epilepsy, today announced the pricing of its initial public offering of 6,000,000 shares of common stock at a public offering price of $17.00 per share
-
Seegene to supply COVID-19 diagnostic tests worth 16 mil. GBP to Scotland, triple the sales volume seen last year
4/22/2021
Seegene Inc. (KQ 096530), a leading biotechnology firm said it began supplying its COVID-19 diagnostic tests worth 16,209,150 GBP to Scotland under a public procurement agreement, the largest diagnostic volume seen in that r
-
The NDA of the Novel Anti-PD-1 mAb Serplulimab of Henlius Accepted by NMPA and Proposed to be Granted Priority Review
4/22/2021
Shanghai Henlius Biotech, Inc. (2696.HK) announced that the New Drug Application (NDA) of serplulimab injection (HLX10), a novel anti-PD-1 monoclonal antibody (mAb), for the treatment of unresectable or metastatic microsatellite instability-high (MSI-H) solid tumors that fail to respond to the standard therapy, has been accepted by the National Medical Products Administration (NMPA) and proposed to be granted priority review.
-
Aptorum Group Enters Into Material Transfer and Exclusive Option-To-License Agreement with Yale University for Its Novel Immunomodulators Potentially Targeting Autoimmune and Oncology Diseases
4/22/2021
Aptorum Group Limited, a clinical-stage biopharmaceutical company, through its affiliate, has entered into a material transfer and option agreement with Yale University to evaluate a group of preclinical stage novel immunomodulators.
-
ImmunityBio Announces 100th Patient Dosed with Proprietary Natural Killer Cells; NK Trials Cover Multiple Indications
4/22/2021
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced it has administered its proprietary Natural Killer cells to more than 100 patients.
-
Veeva Unveils Quality Content Reference Model to Empower Companies with Proven Best Practices
4/22/2021
Industry best practices refined from over 300 customer implementations now publicly available to companies modernizing their quality systems
-
Multi-Cancer Early Detection (MCED) Consortium to Chart Path Forward for Use of New Technologies to Improve Early Cancer Detection
4/22/2021
A group of leading public and private cancer-focused organizations today announced a Multi-Cancer Early Detection (MCED) consortium to evaluate new technologies that have the potential to reduce cancer mortality by enabling earlier detection of cancer before it has spread, when treatment is potentially curative.
-
AIkido Pharma Announces Withdrawal of S-1 Registration Statement
4/22/2021
AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the Company has withdrawn its S-1 Registration Statement that was previously filed with the U.S. Securities and Exchange Commission ("SEC").
-
Current Health Closes Oversubscribed $43M Series B Financing Round to Scale Remote Care Management Platform
4/22/2021
Current Health – the leading enterprise remote care management platform – today announced it has raised $43M in Series B financing
-
Summus Global Raises $21 Million in Series B Funding to Transform Employer Health Benefit Landscape with Innovative Virtual Specialty Care Solution
4/22/2021
Summus Global, the leading virtual specialist platform, announced today that it has raised $21M in Series B funding.
-
Hoth Therapeutics' First in Human Clinical Trial for the Treatment of Atopic Dermatitis with BioLexa is Underway
4/22/2021
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is pleased to announce the start of its First in Human clinical trial investigating topical BioLexa for the treatment of mild to moderate atopic dermatitis, also known as eczema.
-
Cigna Introduces Broad Incentives to Encourage COVID-19 Vaccination
4/22/2021
Cigna is introducing a broad range of new initiatives to encourage and expand access to COVID-19 vaccinations.
-
EDGe Surgical Granted U.S. Patent for Next-Generation Awl-in-One Tap™
4/22/2021
EDGe Surgical, Inc., a company focused on developing and manufacturing smart orthopedic and spine surgical instruments, announced today that its next-generation Awl-in-One Tap™ device has been granted patent 10,912,483 titled “Handheld devices for use in medical procedures” by the United States Patent and Trademark Office.
-
CareDx to Debut Multicenter Data on AlloSure® Lung, an Analytically and Clinically Validated Biomarker of Graft Injury for Lung Transplant Patients
4/22/2021
Leading transplant clinicians to present data in seven abstracts at International Society of Heart and Lung Transplantation Annual Meeting
-
Agilent LC/MS Instruments Receive ACT Labels from My Green Lab
4/22/2021
Agilent Technologies Inc. (NYSE: A) announced today that both the InfinityLab LC/MSD iQ and the Ultivo Triple Quadrupole LC/MS systems have earned the highly-respected Accountability, Consistency and Transparency (ACT) Label from My Green Lab, a nonprofit organization dedicated to improving the sustainability of scientific research.
-
Getinge receives US FDA 510(k) clearance for three products, expanding the Servo ventilator platform
4/22/2021
Today, Getinge announces clearance from the US FDA of several new software options for the Servo-u and Servo-n ventilators. In addition to the latest software upgrades, Getinge also received clearance for the new Servo-u MR ventilator for the MRI room.
-
Alvalux Awarded Second U.S. Patent Wearable Light Therapy Device for Eye Disease
4/22/2021
Alvalux Medical, a Belgian medtech wearables company, announced today that it has been awarded its second Patent from the United States Patent and Trademark Office for its wearable ocular insert device.